PMC7562793_01
Magnetic resonance imaging conducted at first diagnosis showing soft tissue-masses (yellow arrows) with infiltration of the right humerus (A) and the right pleura (B).
fonc-10-585830-g001.jpg
PMC7562793_01_fonc-10-585830-g001.jpg
F1
Magnetic resonance imaging (MRI) showed a tumor mass with infiltration of the right humerus (Figure 1A) and the right pleura (Figure 1B).
FDG-Positron emission imaging at first relapse of ALCL showing hypermetabolic lesions around the spine (A) and within the right scapula (B).
fonc-10-585830-g002.jpg
PMC7562793_01_fonc-10-585830-g002.jpg
F2
FDG-Positron emission tomography (FDG-PET) revealed multiple hypermetabolic osteolytic lesions affecting the spine (Figure 2A), several ribs (Figure 2A) and the right scapula (Figure 2B).
Photographic documentation and positron emission imaging at second relapse of ALCL (A,B) and at 3 months after start of crizotinib treatment (C,D).
fonc-10-585830-g003.jpg
PMC7562793_01_fonc-10-585830-g003.jpg
F3
Physical examination revealed a red and swollen left forefoot with tenderness upon palpation (Figure 3A). Subsequent staging via FDG-PET revealed tracer uptake in the left forefoot (Figure 3B) as well as pathological lymph-nodes in the left groin. Over the course of 3 months the cutaneous lesion on the left forefoot vanished (Figure 3C), and FDG-PET-staging showed metabolic complete remission (Figure 3D).